Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

AEterna releases interim phase I/II data for Psovascar

Sep. 14, 1998

Immune Response presents phase II data on psoriasis treatment

Sep. 11, 1998

RXR/RAR receptor modulators claimed by CIRD Galderma for skin and other disorders

Sep. 9, 1998

Biotech Australia announces encouraging early clinical trial results with leg ulcer treatment

Sep. 4, 1998

Leo describes potent vitamin D3 derivatives with low calcemic activity

Sep. 3, 1998

Keratinocyte growth factor to enter phase II clinical trials

Sep. 3, 1998

Access signs development agreement with ViroTex for amlexanox formulations

Sep. 1, 1998

Access signs licensing agreement with Paladin to market amlexanox in Canada

Aug. 27, 1998

Incert appears to prevent the formation of postoperative adhesions

Aug. 26, 1998

Toray reports kappa agonists for treating dermatological disorders

Aug. 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...